Please enter the email address you used to register, then we will send you a link to choose a new password
BMO Capital analyst Etzer Darout reiterates C4 Therapeutics (NASDAQ:CCCC) with a Outperform and maintains $20 price target.
C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d...
Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Equal-Weight and raises the price target fr...
Stifel analyst Bradley Canino maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $13 to $14.